Home Newsfeeds Cowen & Co. Upgrades Absci to Outperform

Cowen & Co. Upgrades Absci to Outperform

Cowen & Co. analyst Steven Mah upgrades Absci (NASDAQ:ABSI) from Market Perform to Outperform.

byBenzinga Newsdesk

August 12, 2022

1 minute read

Cowen & Co. analyst Steven Mah upgrades Absci (NASDAQ:ABSI) from Market Perform to Outperform.

M&A
News

Earlier Announced Allkem Shareholders Vote In Favor Of Merger With Livent

By Benzinga Newsdesk

December 19, 10:30 AM

Allkem Limited (ASX: AKE, "Allkem") refers to the proposed merger of equals between Allkem and Livent Corporation ("Livent"), ("Transaction"). Allkem is pleased to announce that the requisite majorities of Allkem

LTHM

Brainstorm Cell Therapeutics Announces Pricing Of $7.5M Registered Direct Offering For The Purchase And Sale Of 4,054,055 Shares Of Common Stock And Warrants At A Price Of $1.85/Share, Warrants Will Have An Excersize Price Of $2/Share

By Happy Mohamed

July 17, 9:16 AM

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has entered into a securities

BCLI

York Water Q3 EPS $0.40 Up From $0.36 YoY, Sales $15.81M Up From $14.50M YoY

By Benzinga Newsdesk

November 3, 9:41 AM

York Water (NASDAQ:YORW) reported quarterly earnings of $0.40 per share. This is a 11.11 percent increase over earnings of $0.36 per share from the same period last year. The company reported $15.81 million in sales

YORW